A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
Latest Information Update: 31 May 2024
At a glance
- Drugs Ulotaront (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Otsuka America Pharmaceutical; Otsuka Pharmaceutical Development & Commercialization
- 01 Dec 2022 According to an Otsuka Pharmaceutical media release, first patient has been enrolled.
- 14 Nov 2022 Planned End Date changed from 21 Jan 2025 to 1 May 2025.
- 14 Nov 2022 Planned primary completion date changed from 14 Jan 2025 to 1 May 2025.